PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $26 | $15 | $22 | $96 |
| - Cash | $10 | $0 | $25 | $39 |
| + Debt | $11 | $0 | $3 | $14 |
| Enterprise Value | $27 | $15 | $0 | $70 |
| Revenue | $0 | $0 | – | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | – | -$2 |
| % Margin | – | – | – | – |
| EBITDA | -$12 | -$5 | – | -$6 |
| % Margin | – | – | – | – |
| Net Income | -$11 | -$6 | – | $6 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.72 | 0 | – | 0.19 |
| % Growth | – | – | – | – |
| Operating Cash Flow | -$13 | – | – | -$11 |
| Capital Expenditures | -$0 | – | – | -$0 |
| Free Cash Flow | -$13 | – | – | -$11 |